Tubuloglomerular feedback (TGF) stabilizes nephron function from minute to minute and adapts to different steady-state inputs to maintain this capability. Such adaptation inherently renders TGF less efficient at buffering long-term disturbances, but the magnitude of loss is unknown. We undertook the present study to measure the compromise between TGF and TGF adaptation in transition from acute ...

Penyakit metabolik yang melibatkan insulin dikenal dengan diabetes mellitus (DM) merupakan suatu gangguan pada metabolisme karbohidrat, lemak dan protein berakibat peningkatan kadar glukosa darah. Diabetes melitus dapat dipengaruhi oleh beberapa faktor yaitu usia, obesitas, riwayat keluarga, glukosa, gaya hidup. Tujuan dilakukan penelitian ini untuk mengetahui bagaimana efek setelah pemberian d...

BACKGROUND The recently published cardiovascular outcomes data for the first sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, have shown cardiovascular safety and additional benefits in patients with type 2 diabetes and established cardiovascular disease. Empagliflozin showed lower rates of death from cardiovascular causes or from any causes and lower hospitalization rates from ...

BACKGROUND Current treatment of hyperglycemia in type 2 diabetes (T2DM) is often ineffective and has unwanted effects. Therefore, novel antidiabetic drugs are under development. OBJECTIVE To assess efficacy and safety of the new antidiabetic drugs sodium glucose co-transport-2 (SGLT2) inhibitors in T2DM. Design and setting. Among 151 articles published on MEDLINE, Cochrane Library, EMBASE, Pu...

Dapagliflozin was the first of its class (inhibitors of sodium-glucose cotransporter) to be approved in Europe, USA, and Brazil. As the drug was recently approved, there is the need for research on analytical methods, including dissolution studies for the quality evaluation and assurance of tablets. The dissolution methodology was developed with apparatus II (paddle) in 900 mL of medium (simula...

Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitors used in the treatment of patients with type 2 diabetes. An aryl glycoside significant effect as glucose-lowering agents, also has indication for Heart Failure and Chronic Kidney Disease. This review examines structure, synthesis, analysis, structure activity relationship uses product. The studies behind this drug have opened ...

OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney cardiovascular with dapagliflozin versus placebo participants chronic disease (CKD) without diabetes. We compared according to baseline glycemic status. RESEARCH DESIGN AND METHODS enrolled CKD, estimated glomerular filtration rate (eGFR) 25–75 mL/min/...